12:00 AM
 | 
Oct 29, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Kevetrin thioureidobutyronitrile: Phase I started

Cellceutix began an open-label, dose-escalation, U.S. Phase I trial to evaluate IV Kevetrin given once weekly for the first 3 weeks of a 4-week cycle in about 40 patients with advanced solid tumors. In March, Cellceutix...

Read the full 156 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >